Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487

1.

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline.

Gordon CE, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, Earley A, Di M, Cheung M, Jadoul M, Martin P.

Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]

PMID:
31546256
2.

Hepatitis E virus infections in Europe.

Izopet J, Tremeaux P, Marion O, Migueres M, Capelli N, Chapuy-Regaud S, Mansuy JM, Abravanel F, Kamar N, Lhomme S.

J Clin Virol. 2019 Sep 8;120:20-26. doi: 10.1016/j.jcv.2019.09.004. [Epub ahead of print]

PMID:
31536936
3.

THETA: A new genotypic approach for predicting HIV-1 CRF02-AG coreceptor usage.

Dimeglio C, Raymond S, Jeanne N, Reynes C, Carcenac R, Lefebvre C, Cazabat M, Nicot F, Delobel P, Izopet J.

Bioinformatics. 2019 Jul 26. pii: btz585. doi: 10.1093/bioinformatics/btz585. [Epub ahead of print]

PMID:
31350559
4.

Transfusion-Transmitted Hepatitis E Virus Infection in France.

Gallian P, Pouchol E, Djoudi R, Lhomme S, Mouna L, Gross S, Bierling P, Assal A, Kamar N, Mallet V, Roque-Afonso AM, Izopet J, Tiberghien P.

Transfus Med Rev. 2019 Jul;33(3):146-153. doi: 10.1016/j.tmrv.2019.06.001. Epub 2019 Jun 20. Review.

PMID:
31327668
5.

Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.

Lhomme S, DebRoy S, Kamar N, Abravanel F, Metsu D, Marion O, Dimeglio C, Cotler SJ, Izopet J, Dahari H.

Viruses. 2019 Jul 9;11(7). pii: E630. doi: 10.3390/v11070630.

6.

Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapy.

Raymond S, Jeanne N, Nicot F, Lefebvre C, Carcenac R, Minier L, Chiabrando J, Cazabat M, Delobel P, Izopet J.

AIDS. 2019 Nov 1;33(13):1977-1985. doi: 10.1097/QAD.0000000000002295.

PMID:
31259760
7.

Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso.

Dimeglio C, Kania D, Mantono JM, Kagoné T, Zida S, Tassembedo S, Dicko A, Tinto B, Yaro S, Hien H, Rouamba J, Bicaba B, Medah I, Meda N, Traoré O, Tuaillon E, Abravanel F, Izopet J.

Viruses. 2019 Jun 14;11(6). pii: E554. doi: 10.3390/v11060554.

8.

Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016-2017.

Ngangas ST, Lukashev A, Jugie G, Ivanova O, Mansuy JM, Mengelle C, Izopet J, L'honneur AS, Rozenberg F, Leyssene D, Hecquet D, Marque-Juillet S, Boutolleau D, Burrel S, Peigue-Lafeuille H, Archimbaud C, Benschop K, Henquell C, Mirand A, Bailly JL.

Emerg Infect Dis. 2019 Jun;25(6):1204-1208. doi: 10.3201/eid2506.181460.

9.

Viral load and clinical manifestations of hepatitis E virus genotype 3 infections.

Lhomme S, Gallian P, Dimeglio C, Assal A, Abravanel F, Tiberghien P, Izopet J.

J Viral Hepat. 2019 Sep;26(9):1139-1142. doi: 10.1111/jvh.13128. Epub 2019 Jun 10.

PMID:
31099059
10.

Screening, diagnosis and risks associated with Hepatitis E virus infection.

Lhomme S, Legrand-Abravanel F, Kamar N, Izopet J.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):403-418. doi: 10.1080/14787210.2019.1613889. Epub 2019 May 13.

PMID:
31082277
11.

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis.

Sayed IM, Verhoye L, Montpellier C, Abravanel F, Izopet J, Cocquerel L, Meuleman P.

J Infect Dis. 2019 Jul 31;220(5):811-819. doi: 10.1093/infdis/jiz171.

PMID:
31001628
12.

No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.

Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Aug;21(4):e13093. doi: 10.1111/tid.13093. Epub 2019 Apr 30.

PMID:
30972874
13.

Peripheral Plasma and Semen Cytokine Response to Zika Virus in Humans.

Mansuy JM, El Costa H, Gouilly J, Mengelle C, Pasquier C, Martin-Blondel G, Izopet J, Jabrane-Ferrat N.

Emerg Infect Dis. 2019 Apr;25(4):823-825. doi: 10.3201/eid2504.171886.

14.

Increased CXCR3+ T Cells Impairs Recruitment of T-Helper Type 17 Cells via Interferon γ and Interleukin 18 in the Small Intestine Mucosa During Treated HIV-1 Infection.

Loiseau C, Requena M, Nayrac M, Mavigner M, Cazabat M, Iscache AL, Carrere N, Suc B, Alric L, Izopet J, Delobel P.

J Infect Dis. 2019 Jul 31;220(5):830-840. doi: 10.1093/infdis/jiz123.

PMID:
30880342
15.

[Hepatitis E virus infection].

Marion O, Izopet J, Kamar N.

Rev Prat. 2018 Mar;68(3):286-290. French.

PMID:
30869287
16.

Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?

Marion O, Lhomme S, Abravanel F, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Jun;21(3):e13065. doi: 10.1111/tid.13065. Epub 2019 Mar 22. No abstract available.

PMID:
30860299
17.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1417-1424. doi: 10.1093/jac/dkz011.

PMID:
30753724
18.

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy.

Guerveno C, Raymond S, Metsu D, Gandia P, Izopet J, Martin-Blondel G, Delobel P.

AIDS. 2019 Mar 1;33(3):593-594. doi: 10.1097/QAD.0000000000002089. No abstract available.

PMID:
30702524
19.

Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection.

Marion O, Abravanel F, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Apr;21(2):e13050. doi: 10.1111/tid.13050. Epub 2019 Feb 4. No abstract available.

PMID:
30663838
20.

Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients.

Marion O, Capelli N, Lhomme S, Dubois M, Pucelle M, Abravanel F, Kamar N, Izopet J.

J Infect. 2019 Mar;78(3):232-240. doi: 10.1016/j.jinf.2019.01.004. Epub 2019 Jan 17.

PMID:
30659856
21.

Performance characteristics of the VIDAS® ANTI-HEV IgM and IgG assays.

Abravanel F, Goutagny N, Joffray R, Eichenlaub E, Baron S, Aversenq A, Bourg S, Mercier L, Larue Triolet A, Poirault D, Loubet M, Daniel S, Luciani F, Pothion C, Tourneur C, Dugua JM, Lhomme S, Izopet J.

J Clin Virol. 2019 Mar;112:10-14. doi: 10.1016/j.jcv.2019.01.005. Epub 2019 Jan 11.

PMID:
30658273
22.

Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.

Marion O, Lhomme S, Del Bello A, Abravanel F, Esposito L, Hébral AL, Lavayssière L, Cointault O, Ribes D, Izopet J, Kamar N.

J Hepatol. 2019 Jan;70(1):206-209. doi: 10.1016/j.jhep.2018.09.011. Epub 2018 Oct 24. No abstract available.

PMID:
30563687
23.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

Dimeglio C, Raymond S, Nicot F, Jeanne N, Carcenac R, Lefebvre C, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group .

J Antimicrob Chemother. 2019 Mar 1;74(3):718-721. doi: 10.1093/jac/dky495.

PMID:
30535228
24.

Hepatitis E prevalence in French Polynesian blood donors.

Dimeglio C, Beau F, Broult J, Gouy P, Izopet J, Lastère S, Abravanel F.

PLoS One. 2018 Dec 7;13(12):e0208934. doi: 10.1371/journal.pone.0208934. eCollection 2018.

25.

CCR5 structural plasticity shapes HIV-1 phenotypic properties.

Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, Benureau Y, Gonzalez N, Jin J, Connell BJ, Raymond S, Delobel P, Izopet J, Lortat-Jacob H, Alcami J, Arenzana-Seisdedos F, Brelot A, Lagane B.

PLoS Pathog. 2018 Dec 6;14(12):e1007432. doi: 10.1371/journal.ppat.1007432. eCollection 2018 Dec.

26.

Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes.

Capelli N, Marion O, Dubois M, Allart S, Bertrand-Michel J, Lhomme S, Abravanel F, Izopet J, Chapuy-Regaud S.

J Virol. 2019 Feb 5;93(4). pii: e01207-18. doi: 10.1128/JVI.01207-18. Print 2019 Feb 15.

27.

Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface.

Gouilly J, Chen Q, Siewiera J, Cartron G, Levy C, Dubois M, Al-Daccak R, Izopet J, Jabrane-Ferrat N, El Costa H.

Nat Commun. 2018 Nov 12;9(1):4748. doi: 10.1038/s41467-018-07200-2.

28.

Performance of a commercial assay for detecting and quantifying HEV RNA in faeces.

Abravanel F, Lacipière A, Lhomme S, Dubois M, Minier L, Peron JM, Alric L, Kamar N, Izopet J.

J Clin Virol. 2018 Dec;109:1-5. doi: 10.1016/j.jcv.2018.10.003. Epub 2018 Oct 10.

PMID:
30336371
29.

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.

Jadoul M, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, Gordon CE, Earley A, Di M, Martin P.

Kidney Int. 2018 Oct;94(4):663-673. doi: 10.1016/j.kint.2018.06.011.

30.

Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing.

Raymond S, Delaugerre C, Nicot F, Assoumou L, Lancar R, Beniguel L, Izopet J; ANRS 146 OPTIMAL study group.

AIDS. 2018 Oct 23;32(16):2429-2431. doi: 10.1097/QAD.0000000000001976.

PMID:
30102658
31.

Detection of Zika, dengue and chikungunya viruses using single-reaction multiplex real-time RT-PCR.

Mansuy JM, Lhomme S, Cazabat M, Pasquier C, Martin-Blondel G, Izopet J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):284-287. doi: 10.1016/j.diagmicrobio.2018.06.019. Epub 2018 Jun 28.

PMID:
30029808
32.

Acute hepatitis E in French patients and neurological manifestations.

Abravanel F, Pique J, Couturier E, Nicot F, Dimeglio C, Lhomme S, Chiabrando J, Saune K, Péron JM, Kamar N, Evrard S, de Valk H, Cintas P, Izopet J; HEV study group.

J Infect. 2018 Sep;77(3):220-226. doi: 10.1016/j.jinf.2018.06.007. Epub 2018 Jul 10.

PMID:
29966614
33.

A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces.

Abravanel F, Lhomme S, Chapuy-Regaud S, Mansuy JM, Boineau J, Sauné K, Izopet J.

J Clin Virol. 2018 Aug;105:109-111. doi: 10.1016/j.jcv.2018.06.013. Epub 2018 Jun 22.

PMID:
29957544
34.

Diversity of hepatitis E virus genotype 3.

Nicot F, Jeanne N, Roulet A, Lefebvre C, Carcenac R, Manno M, Dubois M, Kamar N, Lhomme S, Abravanel F, Izopet J.

Rev Med Virol. 2018 Sep;28(5):e1987. doi: 10.1002/rmv.1987. Epub 2018 Jun 25.

PMID:
29939461
35.

Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients.

Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, Alric L, Faguer S, Izopet J, Kamar N.

Liver Int. 2018 Dec;38(12):2178-2189. doi: 10.1111/liv.13894. Epub 2018 Jun 14.

PMID:
29845733
36.

Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation.

Grellier J, Hirsch HH, Mengelle C, Esposito L, Hebral AL, Bellière J, Weissbach F, Izopet J, Del Bello A, Kamar N.

Transpl Infect Dis. 2018 Aug;20(4):e12917. doi: 10.1111/tid.12917. Epub 2018 Jun 11.

PMID:
29800505
37.

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L.

Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382.

PMID:
29767684
38.

Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene.

Nicot F, Jeanne N, Raymond S, Delfour O, Carcenac R, Lefebvre C, Sauné K, Delobel P, Izopet J.

J Med Virol. 2018 Sep;90(9):1486-1492. doi: 10.1002/jmv.25224. Epub 2018 May 25.

PMID:
29750364
39.

Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients: A Retrospective Cohort Study.

Mallet V, Sberro-Soussan R, Roque-Afonso AM, Vallet-Pichard A, Deau B, Portal A, Chaix ML, Hauser L, Beylouné A, Mercadier A, Izopet J, Legendre C, Pol S.

Transplantation. 2018 Aug;102(8):1351-1357. doi: 10.1097/TP.0000000000002185.

PMID:
29561324
40.

Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections.

Dalton HR, Izopet J.

Cold Spring Harb Perspect Med. 2018 Nov 1;8(11). pii: a032144. doi: 10.1101/cshperspect.a032144. Review.

PMID:
29530946
41.

Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015.

Bisseux M, Colombet J, Mirand A, Roque-Afonso AM, Abravanel F, Izopet J, Archimbaud C, Peigue-Lafeuille H, Debroas D, Bailly JL, Henquell C.

Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.17-00237.

42.

HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.

Raymond S, Nicot F, Carcenac R, Lefebvre C, Jeanne N, Saune K, Delobel P, Izopet J.

J Antimicrob Chemother. 2018 May 1;73(5):1152-1157. doi: 10.1093/jac/dky003.

PMID:
29444253
43.

[HEV and transfusion-recipient risk].

Izopet J.

Ann Pharm Fr. 2018 Mar;76(2):89-96. doi: 10.1016/j.pharma.2017.12.007. Epub 2018 Feb 1. Review. French.

PMID:
29395014
44.

A European multicenter study on the analytical performance of the VERIS HBV assay.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Mancon A, Marcos MA, Sauné K, O Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D.

J Clin Virol. 2018 Feb - Mar;99-100:50-56. doi: 10.1016/j.jcv.2017.12.009. Epub 2017 Dec 19.

PMID:
29328964
45.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group.

Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070.

PMID:
29244143
46.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.

de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group.

J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.

PMID:
29186458
47.

Hepatitis E virus infection.

Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR.

Nat Rev Dis Primers. 2017 Nov 16;3:17086. doi: 10.1038/nrdp.2017.86. Review.

PMID:
29154369
48.

Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated?

Kamar N, Del Bello A, Izopet J.

Transplantation. 2018 Feb;102(2):e84-e85. doi: 10.1097/TP.0000000000001994. No abstract available.

PMID:
29135858
49.

Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays.

Pasquier C, Joguet G, Mengelle C, Chapuy-Regaud S, Pavili L, Prisant N, Izopet J, Bujan L, Mansuy JM.

Diagn Microbiol Infect Dis. 2018 Jan;90(1):26-30. doi: 10.1016/j.diagmicrobio.2017.09.001. Epub 2017 Sep 15.

PMID:
29107414
50.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

J Hepatol. 2018 Mar;68(3):595-597. doi: 10.1016/j.jhep.2017.09.019. Epub 2017 Oct 4. No abstract available.

PMID:
28987520

Supplemental Content

Loading ...
Support Center